Show simple item record

AuthorFatokun, Omotayo
AuthorIbrahim, Mohamed Izham Mohamed
AuthorHassaii, Mohamed Azmi
Available date2021-09-05T05:40:22Z
Publication Date2016
Publication NameGaBI Journal
ResourceScopus
ISSN20336403
URIhttp://dx.doi.org/10.5639/gabij.2016.0504.046
URIhttp://hdl.handle.net/10576/22747
AbstractDue to the rising costs of pharmaceuticals and a prevailing economic crisis, the availability of generic equivalents of trademark innovator medicines has become crucial to the Malaysian healthcare system. In 2003, Malaysia became the first country in Asia to issue a compulsory licence for the importation of generic versions of patented antiretroviral medicines, following the adoption of the World Trade Organization (WTO) Doha declaration on the Trade-Related Aspects of Intellectual Property lights (TRIPS) agreement and public health. [1, 2]. This action was taken to increase access to affordable antiretroviral medicines, patented forms of which were highly priced. As a result of the licence, the average treatment costs per HIV-infected patient per month in public hospitals declined by up to 83% and there were widespread reductions in the prices of innovator patented antiretroviral products [1, 31-Nevertheless, issues surrounding pharmaceutical patents mean medicine accessibility and generics availability continue to be a challenge in Malaysia [2]. 2016 Pro Pharma Communications International.
Languageen
PublisherPro Pharma Communications International
SubjectGeneric medicines
Malaysia
Market entry
Patent
Pharmaceutical market
TitleGeneric medicines entry into the Malaysian pharmaceutical market
TypeArticle
Pagination180-181
Issue Number4
Volume Number5
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record